Abstract
Brefeldin A (BFA) is an fungal antibiotic that induces ER stress in eukaryotic cells. Cancer stem cells (CSCs) have indefinite potential for self-renewal and the capability to drive tumorigenesis. The effects of BFA on CSCs have not been fully investigated. In this article we investigated the inhibitory effects of BFA on human lung cancer A549 and H1299 cells. Cytotoxicity toward suspension cultures has been used as a method for the preliminary screening of drugs targeting CSCs. We showed that BFA effectively reduced the survival of suspension A549 cells (EC50 =~30 ng/ml) by inducing apoptosis, and inhibited the clonogenic activity of A549 and H1299 CSCs at the same concentration range. We also demonstrated that BFA reduced the migration ability of A549 and H1299 cells. These results suggest that BFA can effectively suppress the progression of lung cancer during tumorigenesis and metastasis. The results of this study may help develop novel therapy for future treatment of lung cancer.
Keywords: Apoptosis, Brefeldin A, cancer stem cell, clonogenesis, lung cancer, migration.
Current Signal Transduction Therapy
Title:Brefeldin A Inhibits Cancer Stem Cell Properties in Human Lung Cancer Cells
Volume: 8 Issue: 2
Author(s): Chao-Neng Tseng, Chung-Lung Cho, Tzan-Wen Chen, Chien-Chih Chiu, Hsueh-Wei Chang, Fang-Rong Chang and Yung-Fu Chang
Affiliation:
Keywords: Apoptosis, Brefeldin A, cancer stem cell, clonogenesis, lung cancer, migration.
Abstract: Brefeldin A (BFA) is an fungal antibiotic that induces ER stress in eukaryotic cells. Cancer stem cells (CSCs) have indefinite potential for self-renewal and the capability to drive tumorigenesis. The effects of BFA on CSCs have not been fully investigated. In this article we investigated the inhibitory effects of BFA on human lung cancer A549 and H1299 cells. Cytotoxicity toward suspension cultures has been used as a method for the preliminary screening of drugs targeting CSCs. We showed that BFA effectively reduced the survival of suspension A549 cells (EC50 =~30 ng/ml) by inducing apoptosis, and inhibited the clonogenic activity of A549 and H1299 CSCs at the same concentration range. We also demonstrated that BFA reduced the migration ability of A549 and H1299 cells. These results suggest that BFA can effectively suppress the progression of lung cancer during tumorigenesis and metastasis. The results of this study may help develop novel therapy for future treatment of lung cancer.
Export Options
About this article
Cite this article as:
Tseng Chao-Neng, Cho Chung-Lung, Chen Tzan-Wen, Chiu Chien-Chih, Chang Hsueh-Wei, Chang Fang-Rong and Chang Yung-Fu, Brefeldin A Inhibits Cancer Stem Cell Properties in Human Lung Cancer Cells, Current Signal Transduction Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/15743624113086660005
DOI https://dx.doi.org/10.2174/15743624113086660005 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Current Cancer Drug Targets Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics Nucleoside Phosphorylases
Current Organic Chemistry Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy
Current Pharmaceutical Design Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Current Pharmaceutical Design Targeting the Microglial Signaling Pathways: New Insights in the Modulation of Neuropathic Pain
Current Medicinal Chemistry Multimerization Improves Targeting of Peptide Radio-Pharmaceuticals
Current Pharmaceutical Design The Role of miRNAs in Plasma Cell Dyscrasias
MicroRNA Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry Breath Tests in Diagnosis of Pulmonary Tuberculosis
Recent Patents on Biotechnology New Approved Medications for Idiopathic Pulmonary Fibrosis
Current Drug Therapy Triggered Activation and Release of Liposomal Prodrugs and Drugs in Cancer Tissue by Secretory Phospholipase A2
Current Drug Delivery Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine A Systematic Review of Meta-Analyses on Gene Polymorphisms and Gastric Cancer Risk
Current Genomics Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets